Under construction – not a live service
Sign in
Taking peoplePhase 2

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Key facts

Where
Barrie, Edmonton, Markham, Québec, Richmond Hill, Saskatoon, Surrey, and Winnipeg, CanadaSee the 8 sites
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07766005, who can take part

Where in Canada

  • Barrie, OntarioHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting
  • Edmonton, AlbertaHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting
  • Markham, OntarioHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting
  • Québec, QuebecHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting
  • Richmond Hill, OntarioHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting
  • Saskatoon, SaskatchewanHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting
  • Surrey, British ColumbiaHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting
  • Winnipeg, ManitobaHospital not named in the registryContact: SKYLIGHT Trial CenterNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Spyre Therapeutics, Inc.
Trial code
NCT07766005
Record updated
19 October 2026
Original description
This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.Read full original descriptionShow less

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment

This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.

Inclusion: Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening; Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1; Total abscess and/or inflammatory nodule count of at least 5 at screening and Day 1; Documented inadequate response, intolerance, or contraindication to at least 1 systemic therapy for hidradenitis suppurativa.

Exclusion: Hidradenitis suppurativa lesion expected to require incision and drainage within 4 weeks before Day 1, or major hidradenitis suppurativa surgery within 12 weeks before Day 1; Another inflammatory or skin condition that could interfere with assessment of hidradenitis suppurativa; More than 20 draining tunnels at screening or Day 1.

ClinicalTrials.gov NCT07766005